According to a recent report by in-PharmaTechnologist.com, The European Commission (EC) sought a mandate from European Union member states to negotiate the new Anti-Counterfeiting Trade Agreement (ACTA) with major trading partners including the U.S., Japan, Korea, Mexico, and New Zealand.
"The EC has voiced particular concern regarding the growing incidence of fake pharmaceutical products filtering onto the market," says the report. "This sharp rise in fake drugs has led the EC to place particular emphasis on dealing with counterfeit medicines and the harmful, potentially fatal, effects they can have on consumers.
"The ACTA agreement hopes to pull the international community together to create a united front to fight the scourge of counterfeits affecting all industries, and enforce global intellectual property rights," the report notes.
Read more about anti-counterfeiting at www.healthcarepackaging.com/go/19
